'Groundbreaking Option' Approved for Rectal Cancer

Jemperli Wins Accelerated FDA Approval for a Rectal Cancer Subtype as Most Trial Patients Avoided Surgery

FDA gave Jemperli accelerated approval for dMMR rectal cancer. Most trial patients skipped surgery, but the data are interim. What patients should ask.

'Groundbreaking Option' Approved for Rectal Cancer

(MedPage Today) -- The FDA on Monday granted accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) to help select patients with operable rectal cancer potentially avoid surgery. The approval allows use in stage II/III patients with...

AnaptysBio Shares Rise After FDA Expands Jemperli Approval

The accelerated approval adds a use for GSK’s cancer treatment in a type of rectal cancer.

Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer

FDA’s conditional approval of Jemperli (dostarlimab-gxly) rests on a single-arm phase 2 trial, with independent-review data still maturing.